Association Between S-1 Treatment Duration and Disease Control in Advanced Non-small-cell Lung Cancer.
- 1Department of Respiratory Medicine, Kanazawa Medical University, Uchinada-machi, Ishikawa, Japan.
Abstract
Background/aim
S-1 monotherapy is used for a subset of patients with advanced non-small-cell lung cancer (NSCLC); however, predictors of prolonged treatment and survival remain unclear. The aim of this study was to investigate clinical factors associated with extended S-1 treatment and clinical outcomes in patients with advanced NSCLC.Patients and methods
We retrospectively reviewed the data of 32 patients with stage IIIB/IV or recurrent NSCLC who received S-1 monotherapy at Kanazawa Medical University Hospital from January 2015 and December 2025. Patients were classified into a long-term treatment group (≥90 days, n=13) or a short-term treatment group (<90 days, n=19).Results
Overall, the median duration of treatment was 103.4 days (range=12-342 days), the objective response rate was 12.5%, and the disease control rate was 46.9%. Baseline characteristics were generally comparable between the two groups. The study endpoints, including disease control rate and overall survival, were significantly improved in the long-term treatment group. The disease control rate was significantly higher for the long-term group than for the short-term group (84.6% vs. 21.1%, p=0.001). The median overall survival was also significantly longer for the long-term group (1,529 vs. 733 days, p=0.003). Treatment-related adverse events were mild: no grade ≥3 toxicities or treatment-related deaths were observed.Conclusion
Prolonged S-1 treatment was associated with improved disease control and longer overall survival in patients with advanced NSCLC. These findings suggest that disease stabilization, rather than tumor shrinkage, may be a key determinant of the long-term benefit of S-1 monotherapy.
Related
- Non-linear association between average daily sleep duration and cardiovascular disease in patients with diabetes or prediabetes
- NOD2 Variants and Duration of Hospitalization After Endoscopic Treatment of Biliary Strictures Following Liver Transplantation: A Cutoff-Dependent Association.
- Association of antifungal treatment duration with 90-day mortality in critically ill adults with candidemia: a multicenter target trial emulation in France
- Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
- Shared Decision-Making and Decision Support in Advanced Chronic Kidney Disease: A Systematic Review of Models, Treatment Pathways, and Patient-Centered Outcomes
BibTeX
@article{takahara2026association,
title = {{Association Between S-1 Treatment Duration and Disease Control in Advanced Non-small-cell Lung Cancer.}},
author = {Yutaka Takahara and Ryudai Abe and Sumito Nagae and Takuya Tanaka and Yoko Ishige and Ikuyo Shionoya and Kouichi Yamamura and Masaharu Iguchi},
journal = {Cancer diagnosis \& prognosis},
year = {2026},
month = nov,
doi = {10.21873/cdp.10601},
url = {https://europepmc.org/article/MED/42968828},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Association Between S-1 Treatment Duration and Disease Control in Advanced Non-small-cell Lung Cancer.
AU - Yutaka Takahara
AU - Ryudai Abe
AU - Sumito Nagae
AU - Takuya Tanaka
AU - Yoko Ishige
AU - Ikuyo Shionoya
AU - Kouichi Yamamura
AU - Masaharu Iguchi
PY - 2026
DA - 2026/11/01
JO - Cancer diagnosis & prognosis
DO - 10.21873/cdp.10601
UR - https://europepmc.org/article/MED/42968828
AB - Background/aim S-1 monotherapy is used for a subset of patients with advanced non-small-cell lung cancer (NSCLC); however, predictors of prolonged treatment and survival remain unclear. The aim of this study was to investigate clinical factors associated with extended S-1 treatment and clinical outcomes in patients with advanced NSCLC.Patients and methods We retrospectively reviewed the data of 32 patients with stage IIIB/IV or recurrent NSCLC who received S-1 monotherapy at Kanazawa Medical University Hospital from January 2015 and December 2025. Patients were classified into a long-term treatment group (≥90 days, n=13) or a short-term treatment group (<90 days, n=19).Results Overall, the median duration of treatment was 103.4 days (range=12-342 days), the objective response rate was 12.5%, and the disease control rate was 46.9%. Baseline characteristics were generally comparable between the two groups. The study endpoints, including disease control rate and overall survival, were significantly improved in the long-term treatment group. The disease control rate was significantly higher for the long-term group than for the short-term group (84.6% vs. 21.1%, p=0.001). The median overall survival was also significantly longer for the long-term group (1,529 vs. 733 days, p=0.003). Treatment-related adverse events were mild: no grade ≥3 toxicities or treatment-related deaths were observed.Conclusion Prolonged S-1 treatment was associated with improved disease control and longer overall survival in patients with advanced NSCLC. These findings suggest that disease stabilization, rather than tumor shrinkage, may be a key determinant of the long-term benefit of S-1 monotherapy.
SN - 2732-7787
ER -